Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Axial Spondyloarthritis (AxSpA) Clear all
Completed Phase 4 Interventional Results available

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

NCT03350815
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Early Phase 1 Interventional

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

NCT00643526
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions
Pre-filled Auto-injector Containing Placebo
Device
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 2, 2026, 2:30 PM EDT
Withdrawn Phase 3 Interventional

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chronic Pain, Couples, & Physical Activity

NCT04077164
View directory record Official record
Conditions
Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions
No intervention, observational only.
Other
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

NCT02019602
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated Not applicable Interventional

Clinical Investigation of MONTAGE in Adults With Spinal Deformity Undergoing Pedicle Subtraction Osteotomy

NCT04125147
View directory record Official record
Conditions
Fused Vertebrae, Ankylosing Spondylitis, Sagittal Deformities, Thoracolumbar Kyphosis
Interventions
Experimental: Montage Bone Hemostat
Device
Lead sponsor
Abyrx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 2, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of SUNPG1622

NCT02980705
View directory record Official record
Conditions
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Interventions
SUNPG1622 I dose, Placebo dose
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 2:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Development of Spondyloarthritis

NCT01422694
View directory record Official record
Conditions
Arthritis, Spondylitis, Ankylosing
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 2, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728
View directory record Official record
Conditions
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Interventions
Not listed
Lead sponsor
Exactech
Industry
Eligibility
21 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2031
U.S. locations
24
States / cities
Laguna Woods, California • Redwood City, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 2:30 PM EDT
Not listed No phase listed Observational

Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

NCT00328068
View directory record Official record
Conditions
Spondyloarthritis, Spondylarthropathy, Spondylitis, Ankylosing
Interventions
Not listed
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

NCT03129100
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 2, 2026, 2:30 PM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

NCT02696798
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Novel Quantitative MRI for Axial Spondyloarthritis

NCT03778515
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated No phase listed Observational

A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

NCT06715254
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 2, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 2, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OTIS Cimzia Pregnancy Registry

NCT01797224
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 2, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

NCT02696785
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 2, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement

NCT01969188
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 2, 2026, 2:30 PM EDT